https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34542 Tue 26 Mar 2019 15:11:01 AEDT ]]> Delay from treatment start to full effect of immunotherapies for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]> Determinants of therapeutic lag in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]>